Neurocrine Biosciences Inc (NBIX)
139.36
-1.19
(-0.85%)
USD |
NASDAQ |
May 22, 16:00
139.36
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Financing (Quarterly): 69.90M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 69.90M |
| December 31, 2023 | 35.40M |
| September 30, 2023 | 18.80M |
| June 30, 2023 | 2.90M |
| March 31, 2023 | 8.20M |
| December 31, 2022 | 24.60M |
| September 30, 2022 | 11.40M |
| June 30, 2022 | -276.40M |
| March 31, 2022 | 6.10M |
| December 31, 2021 | 1.80M |
| September 30, 2021 | 7.50M |
| June 30, 2021 | 3.00M |
| March 31, 2021 | 15.10M |
| December 31, 2020 | -185.00M |
| September 30, 2020 | 5.40M |
| June 30, 2020 | 15.80M |
| March 31, 2020 | 6.00M |
| December 31, 2019 | 12.40M |
| September 30, 2019 | 13.10M |
| June 30, 2019 | 4.30M |
| March 31, 2019 | 2.60M |
| December 31, 2018 | 1.752M |
| September 30, 2018 | 5.49M |
| June 30, 2018 | 6.123M |
| March 31, 2018 | 16.14M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.60M |
| September 30, 2017 | 3.022M |
| June 30, 2017 | 506.49M |
| March 31, 2017 | 1.531M |
| December 31, 2016 | 0.063M |
| September 30, 2016 | 1.329M |
| June 30, 2016 | 0.936M |
| March 31, 2016 | 0.062M |
| December 31, 2015 | 0.968M |
| September 30, 2015 | 0.74M |
| June 30, 2015 | 1.759M |
| March 31, 2015 | 273.52M |
| December 31, 2014 | 1.732M |
| September 30, 2014 | 0.484M |
| June 30, 2014 | 0.274M |
| March 31, 2014 | 136.24M |
| December 31, 2013 | 0.05M |
| September 30, 2013 | 2.661M |
| June 30, 2013 | 1.625M |
| March 31, 2013 | 0.966M |
| December 31, 2012 | 0.288M |
| September 30, 2012 | 0.118M |
| June 30, 2012 | 0.043M |
| March 31, 2012 | 83.25M |
| December 31, 2011 | 0.022M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-276.40M
Minimum
Jun 2022
69.90M
Maximum
Mar 2024
-9.985M
Average
7.85M
Median
Cash from Financing (Quarterly) Benchmarks
| Globus Medical Inc | -115.72M |
| Inspire Medical Systems Inc | 0.768M |
| AIM ImmunoTech Inc | 2.829M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 130.30M |
| Cash from Investing (Quarterly) | -55.00M |
| Free Cash Flow | 614.40M |
| Free Cash Flow Per Share (Quarterly) | 1.150 |
| Free Cash Flow to Equity (Quarterly) | 30.20M |
| Free Cash Flow to Firm (Quarterly) | 120.48M |
| Free Cash Flow Yield | 4.33% |